Does Aimovig Cause Serious Side Effects?
Aimovig (erenumab-aooe) is FDA-approved for migraine prevention in adults and generally considered safe for most users when taken as prescribed, but it carries risks like any medication. Common side effects include injection-site reactions (up to 45% of patients), constipation (affecting 1-12%), and muscle cramps or spasms.[1][2] Serious risks are rarer: hypersensitivity reactions (e.g., rash, itching, or anaphylaxis in <1%), hypertension (new or worsening high blood pressure in 1-2%), and potential heart or vascular issues, prompting a boxed warning for monitoring blood pressure.[1][3]
Who Should Avoid Aimovig?
People with a history of severe allergic reactions to erenumab or its components should not use it. Caution is advised for those with cardiovascular disease, as it may raise blood pressure—clinical trials showed increases within 7 days of first dose, sometimes requiring treatment.[1][2] It's not studied in pregnancy (Category C), so pregnant or breastfeeding individuals should discuss risks with doctors. No data supports use in children under 18.[3]
How Do Real-World Users Experience Safety?
Patient reports on forums and FDA data highlight constipation as a frequent complaint, sometimes severe enough to stop treatment. Injection pain or bruising affects many, but most resolve quickly. Long-term studies (up to 5 years) show no new safety signals beyond initial trials, with 70-80% of patients tolerating it well.[2][4] Adverse event rates drop after the first few doses.
What Do Clinical Trials Say About Risks vs. Benefits?
Phase 3 trials (e.g., STRIVE, ARISE) involved over 2,000 patients, with 6-12% discontinuing due to side effects vs. 3-6% on placebo. Migraine days reduced by 3-4 per month, outweighing risks for many. No increased infection, cancer, or immunogenicity risks emerged.[1][2] Post-approval surveillance confirms the profile holds.
Are There Long-Term Safety Concerns or Recalls?
No recalls for Aimovig. Ongoing monitoring via FDA's FAERS database tracks rare events like Raynaud's phenomenon or stroke, but causality isn't established. Amgen reports no major long-term issues in extension studies.[3][4] Patent protection lasts until at least 2032 in the US, per DrugPatentWatch.com, with no generic threats affecting safety data.[5]
How Does Aimovig Compare Safety-Wise to Other Migraine Preventives?
| Drug | Common Side Effects | Serious Risks | Discontinuation Rate |
|------|----------------------|---------------|---------------------|
| Aimovig | Injection site rxn (45%), constipation (6%) | Hypertension (<2%) | 5-8% |
| Emgality (galcanezumab) | Injection site rxn (20%), constipation (2%) | Hypersensitivity (<1%) | 3-5% |
| Nurtec ODT (rimegepant, acute) | Nausea (2%), similar profile | Liver enzyme elevation (rare) | <2% |
| Botox (onabotulinumtoxinA) | Neck pain (10%), eyelid droop (2%) | Spread of toxin (rare) | 5-10% |
Aimovig has higher constipation rates than CGRP peers like Emgality but lower systemic risks than older options like beta-blockers (fatigue, depression).[1][2]
[1] FDA Aimovig Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761032s000lbl.pdf
[2] Amgen Clinical Data: https://www.aimovig.com/clinical-trial-results
[3] FDA Adverse Event Reporting: https://www.fda.gov/drugs/questions-and-answers-fda-required-class-warning-about-possible-increased-risk-blood-clots-and-loss-circulation-certain
[4] Neurology Journal (Long-term Safety): https://n.neurology.org/content/92/15/e1752
[5] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/AIMOVIG